Our Trials

Haematology Clinical Trial Unit - Current  Open to recruitment trials as at August 2019

For more information please contact:
Lisa Demosthenous
Haematology Clinical Trial Unit Manager
lisa.demosthenous@svha.org.au
Ph: (03) 9231 3182NBCR registries

Prof Constantine (Con) Tam, MBBS, MD, FRACP, FRCPA
Director of Haematology
constantine.tam@svha.org.au

A/Prof  Hang Quach MBBS (Hons) SpecCertOC FRACP FRCPA MD
Consultant Clinical and Laboratory Haematologist
hang.quach@svha.org.au

Multiple Myeloma

Newly Diagnosed

MM19 (NDMM)

A Phase 3 trial of thalidomide-dexamethasone consolidation versus thalidomide-dexamethasone-Ixazomib consolidation for transplant eligible multiple myeloma patients undergoing a single ASCT as part of front-line therapy

Open to recruitment

PERSEUS EMN17/54767414MMY3014 (NDMM)Phase 3 Study Comparing Daratumumab, Velcade, Lenalidomide, and Dexamethasone (DVRd) vs Velcade, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple Myeloma who are Eligible for High Dose Therapy - The Perseus Trial

Open to recruitment

IrIL (ND MM)

A prospective Phase II study of Isatuximab Rescue for Inadequate response to Lenalidomide and Dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma

Open to recruitment

MM21 (ND MM)

A multicentre, single arm, study of daratumumab-lenalidomide-dexamethasone (DRd) for newly diagnosed transplant eligible multiple myeloma patients who fail bortezomib-based induction therapy.

Open to recruitment

Relapsed Refractory

AbbVie M15-654 (R/R MM)

A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects with Relapsed or Refractory Multiple Myeloma

On Hold

Amgen AMG424 20160445 (R/R MM)

A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety,Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 424 in Subjects with Multiple Myeloma

On Hold

GSK207497 DREAMM 6 (R/R MM)

A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lenalidomide Plus Dexamethasone (Treatment A), or Bortezomib Plus Dexamethasone (Treatment B) in Participants with Relapsed / Refractory Multiple Myeloma

Open to recruitment

CLL & Lymphomas

Treatment Naïve

BGB3111_304 (TN CLL)

An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Open to recruitment

ALLG HD10 (TN HL)

Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 6 cycles of escalated BEACOPP with 6 cycles of BrECADD advanced stage Hodgkin lymphoma; comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD

Open to Recruitment

AUSTIN 1st FLOR (TN FL)

First-line treatment for grade 1-3A Follicular Lymphoma using Opdivo (nivolumab) plus Rituximab: The 1st FLOR study

Open to Recruitment

APML5 (TN APML)

A phase I pharmacokinetic evaluation of oral arsenic trioxide in previously untreated patients with acute promyelocytic leukaemia (ALLG APML5 study)

Open to recruitment

Relapsed Refractory

Ascentage APG-2575-001 (R/R CLL, WM, DLBCL, AML, NHL, MCL)A Phase I Study of the Safety, Tolerability, Pharmacokinetic AND Pharmacodynamic Properties of Orally AdministERed APG-2575 in Patients with hematologic malignancies

Open to recruitment

BGB-3111-305 (R/R CLL)

A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Open to recruitment

Amgen 20140286 - Subcut Blinatumomab (R/R NHL)

A Phase 1b Open-label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma

Open to recruitment

Genentech GO29781 (R/R DLBCL, FL, MZL, NHL, RT, SLL, MCL)

An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Dose of BTCT4465A in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia

Open to recruitment

TG-1701-110 (R/R CLL, WM, NHL )

A Phase 1 Pharmacokinetic and Pharmacodynamics Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients with B-Cell Malignancies

Open to recruitment

MERCK (MK-4280-003) (R/R HL, DLBCL, NHL)

A Phase 1b Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies

Open to recruitment

Registries

Myeloma 1000 Registry

The Myeloma 1000 Project

Open to recruitment

MRDR Registry

Myeloma & Related Diseases Registry

Open to recruitment

NBCR

Australasian Leukemia and Lymphoma Group National Blood Cancer Registry (previously known as AMLM18)

Open to recruitment

Bleeding Disorders

TREATT

TREATT Trial to Evaluate Tranexamic acid therapy in Thrombocytopenia. A double blind randomized controlled trial evaluating the safety and efficacy of Tranexamic acid in patients with hematological malignancies with severe thrombocytopenia.

Open to recruitment